Efficacy and Safety of Sunvozertinib With Anlotinib in EGFR-TKIs Resistant EGFR-sensitive Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC): a Prospective, Single-arm, Phase II Trial

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Sunvozertinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms WUKONG-9

Most Recent Events

20 Mar 2025 Results presented in the Dizal Pharmaceuticals Media Release.
20 Mar 2025 According to a Dizal Pharmaceuticals media release, the trial results from this trial will be presented at the 2025 European Lung Cancer Congress (ELCC 2025) in Paris, March 26-29.
29 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight